Gyre Therapeutics (NASDAQ:GYRE) CEO Ying Luo Sells 10,136 Shares
by Jessica Moore · The Cerbat GemGyre Therapeutics, Inc. (NASDAQ:GYRE – Get Free Report) CEO Ying Luo sold 10,136 shares of the firm’s stock in a transaction that occurred on Wednesday, May 6th. The stock was sold at an average price of $8.04, for a total transaction of $81,493.44. Following the completion of the transaction, the chief executive officer directly owned 2,565,226 shares in the company, valued at approximately $20,624,417.04. The trade was a 0.39% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.
Gyre Therapeutics Trading Down 12.1%
GYRE stock traded down $0.97 during midday trading on Thursday, reaching $7.07. 167,488 shares of the company’s stock traded hands, compared to its average volume of 55,514. Gyre Therapeutics, Inc. has a 52-week low of $6.57 and a 52-week high of $11.78. The stock has a market cap of $685.72 million, a P/E ratio of 707.71 and a beta of 2.03. The stock’s 50-day moving average is $7.58 and its 200 day moving average is $7.69.
Gyre Therapeutics (NASDAQ:GYRE – Get Free Report) last issued its quarterly earnings results on Thursday, May 7th. The company reported ($0.10) earnings per share for the quarter, missing the consensus estimate of ($0.06) by ($0.04). Gyre Therapeutics had a return on equity of 10.85% and a net margin of 4.31%.The business had revenue of $22.52 million for the quarter, compared to analysts’ expectations of $31.61 million. As a group, research analysts expect that Gyre Therapeutics, Inc. will post -0.18 EPS for the current fiscal year.
Wall Street Analysts Forecast Growth
GYRE has been the subject of several recent research reports. Weiss Ratings reissued a “sell (d)” rating on shares of Gyre Therapeutics in a report on Thursday, January 22nd. Wall Street Zen downgraded Gyre Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday, March 14th. Finally, Zacks Research lowered shares of Gyre Therapeutics from a “hold” rating to a “strong sell” rating in a report on Monday, March 16th. Two analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, Gyre Therapeutics has a consensus rating of “Hold” and an average target price of $17.00.
Read Our Latest Report on Gyre Therapeutics
Institutional Trading of Gyre Therapeutics
Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Geode Capital Management LLC boosted its stake in Gyre Therapeutics by 28.6% in the 2nd quarter. Geode Capital Management LLC now owns 401,709 shares of the company’s stock worth $2,953,000 after purchasing an additional 89,390 shares during the period. Charles Schwab Investment Management Inc. raised its position in shares of Gyre Therapeutics by 37.1% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 169,158 shares of the company’s stock valued at $1,194,000 after buying an additional 45,772 shares during the last quarter. Millennium Management LLC purchased a new position in shares of Gyre Therapeutics in the third quarter worth $267,000. State Street Corp lifted its holdings in shares of Gyre Therapeutics by 10.7% in the fourth quarter. State Street Corp now owns 202,225 shares of the company’s stock worth $1,428,000 after buying an additional 19,472 shares in the last quarter. Finally, Lazard Asset Management LLC bought a new position in shares of Gyre Therapeutics during the third quarter worth $111,000. Institutional investors own 23.99% of the company’s stock.
About Gyre Therapeutics
Gyre Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing small-molecule therapies that target lipid biology to treat a range of metabolic, inflammatory and neurodegenerative diseases. The company’s proprietary platform combines lipidomic profiling with drug discovery tools to identify compounds that selectively modulate membrane lipid composition and restore normal protein function in disease-relevant cells.
Gyre’s preclinical pipeline includes programs in nonalcoholic steatohepatitis (NASH), Alzheimer’s disease and autoimmune conditions, reflecting its strategy of applying a unified lipid-targeted approach across multiple therapeutic areas.